<DOC>
	<DOC>NCT01931982</DOC>
	<brief_summary>The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes</brief_summary>
	<brief_title>Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea. Age: 2575 years BMI&gt;25 kg/m2 HbA1c 6,010 % Current treatment with insulin or Dipeptidyl peptidase IV inhibitor. Haemoglobin &lt; 6.5 mmol/l Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CTangiography or regional dysfunction documented during dipyridamol stressechocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study. Allergy towards victoza Â® (liraglutide ), Dipyridamol, Nitroglycerin or rescue medicine: Theophyllin Pregnancy Severe asthma Active cancer Severe comorbidity with limited lifeexpectancy Estimated glomerular filtration rate (eGFR) &lt;60 (measured at baseline) Severe hepatic comorbidity Chronic alcohol abuse Heart failure with a left ventricular ejection fraction &lt;/= 45% Atrial fibrillation Chronic or previous acute pancreatitis Inflammatory bowel disease.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>diabetes, GLP-1, Victoza, CFR, microvascular dysfunction</keyword>
</DOC>